Brown Melinda 4

What Happened
Melinda Brown, a director of Precision BioSciences (DTIL), had 21,000 restricted stock units (RSUs) vest and converted into 21,000 shares of common stock on May 20, 2026 (reported as an exercise/conversion of a derivative, code M). The Form 4 also shows a simultaneous derivative disposition of 21,000 shares at a $0.00 price (reported as a disposition of a derivative instrument). The filing does not report cash proceeds for the disposition.

Key Details

• Transaction date: May 20, 2026 (Form 4 filed May 22, 2026—timely filing).
• Reported transactions: conversion/exercise (M) — acquisition of 21,000 shares; a corresponding derivative disposition of 21,000 shares at $0.00.
• Price/value: acquisition line shows N/A for price; disposition line shows $0.00. No cash sale proceeds or market sale reported.
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes: F1 — RSUs vested on May 20, 2026; F2 — each RSU equals one share of common stock; F3 — RSUs were granted June 3, 2025 and vested per scheduled terms.
• Transaction type explanation: reported as conversion of RSUs (derivative exercise/conversion). The filing does not explain the $0.00 disposition (e.g., withholding, transfer, or internal settlement is not stated).

Context
This event reflects RSU vesting and conversion to common stock rather than an open‑market purchase or sale. Vesting/awards are routine compensation events for insiders and do not by themselves signal a bullish or bearish trading decision. Because no market sale was reported, there is no change in disclosed cash realized from the transaction in this filing.